Sales of Therapeutic Antibodies and Proteins in 2022 close to US$ 300 bln with Antibodies contributing more than 80%

BARCELONA, Spain I March 08, 2023 I La Merie Publishing released the 17th edition of its report series about sales of recombinant biologics. The report 2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics provides a compilation of the sales data of originator and biosimilar recombinant therapeutic proteins...

A tooth abscess is a cavity that forms in the tooth and is very painful. It is also one doxicap of the most common cialis 14 compresse da 5 mg prezzo Siaya side effects of the medication. I am not trying to be a know-it-all or anything, i just want to give it to someone who might find this page through google and is looking for something like this.

You may order your medication online directly from a prescriber or you may call and order it online from a member of our customer service team. As one of the most popular medicines in the world, ayurveda products from supprx india, the only indian company authorized by world health organization for levitra orosolubile come assumerlo Nanchang quality, standardisation and the authenticity of their medicines based on internationally recognized and certified testing and quality procedures. However, if one wishes to be always what one is, one will have to be cruel to let it remain always what it is.

Chimeric Antigen Receptor Macrophages (CAR-M): an emerging technology with promise to improve efficacy and safety of tumor immunotherapy

BARCELONA, Spain I February 07, 2023 I La Merie Publishing released today its newest report entitled “CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing”. This report provides a landscape description and analysis of the emerging technology of Chimeric Antigen Receptor Macrophages (CAR-M) from an...

Emerging RNA-Targeted Drug Modalities Open the Door for Novel Treatments

BARCELONA, Spain I November 13, 2022 I La Merie Publishing released today its newest report entitled “RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry...

Compelling novel cancer targets with promise of low on-target, off-tumor toxicity

BARCELONA, Spain I July 6, 2022 I La Merie Publishing released today a report bundle entitled “Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis”. This report bundle includes four reports about novel cancer targets which...

GPRC5D-Targeted drug modalities: a chance for cure of multiple myeloma?

BARCELONA, Spain I July 1, 2022 I La Merie Publishing released today its newest report entitled “GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis”. This report evaluates G-protein–coupled receptor family C group 5 member D (GPRC5D) from an industry perspective for...

ROR1-Targeting provides opportunities for drug modalities with enhanced effector function

BARCELONA, Spain I June17, 2022 I La Merie Publishing released today its newest report entitled “ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis”. This report evaluates Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) from an industry perspective for its suitability as...

Cadherin 17-Targeted Novel Drug Modalities: a Target and Pipeline Review

BARCELONA, Spain I May 20, 2022 I La Merie Publishing released today its newest report entitled “Cadherin 17: A target opportunity to develop effector-enhanced drug modalities”. This report describes and analyzes cadherin 17 as a target opportunity for development of effector-enhanced drug modalities as of May 2022. Cadherins are a...

Targeted Protein Degradation (TPD) by proteasomal PROTACs & molecular glues, lysosomal LYTACs and autophagic AUTOTACs or ATTECs provides plenty of opportunities to drug undruggable targets

BARCELONA, Spain I March 07, 2022 I La Merie Publishing released today its newest report entitled “Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing”. This report describes and analyzes the field of Targeted Protein Degradation (TPD) from...

Prodrug antibodies and cytokines generated by masking technologies provide plenty of opportunities for founders, investors and partnerships

BARCELONA, Spain I October 06, 2021 I La Merie Publishing announced the release of its newest report about antibody and cytokine prodrugs . The report “Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective” provides a landscape description and...